arrow
M

Markus Hansson

sahlgrenska university hospital
H指数:40
被引数:8,869

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study

Alnuctamab,一种靶向B细胞成熟抗原的双价T细胞结合剂,用于复发或难治性多发性骨髓瘤患者:一项1期首次人体研究的成果

Leukemia
IF13.4
2026-01-070
OAAI
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Teclistamab联合Daratumumab治疗复发或难治性多发性骨髓瘤

2025-12-015
PRE
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases

通过全外显子测序鉴定的347例家族性和早发性多发性骨髓瘤易感基因

Leukemia
IF13.4
2025-11-180
PRE
Deciphering the genetics and mechanisms of predisposition to multiple myeloma

解读多发性骨髓瘤易感性的遗传学和机制

2024-08-052
OAAI
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
2023-09-011
OAAI
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

完全缓解的多发性骨髓瘤患者的纵向最小残留疾病评估-EMN02/HO95 MM试验中NMSG flow-MRD子研究的结果

2022-02-052
OAAI
Germline variants at SOHLH2 influence multiple myeloma risk
2021-04-1911
OAAI